Board of Directors

Our Board of Directors combines pharmaceutical leadership, business development and scientific expertise to guide Contera's strategy.

Jae Young Lee

Chair / Board member

Jae Young Lee has been CEO of Bukwang Pharmaceutical since April 2024, where he leads the CNS business, new growth initiatives and open-innovation partnerships with global pharma and biotech companies. From 2023 to 2025 he was also Chief Strategic Officer of OCI Holdings, overseeing investments, M&A and subsidiaries. Before joining OCI Group in 2019, he spent 17 years as a public prosecutor. He holds a degree in business administration from Seoul National University and an LLM from Columbia Law School.

Paul E.G. Kristjansen, MD, PhD, DMSc

Independent board member

Paul has broad experience across research, clinical development and business strategy, gained at the University of Copenhagen, Harvard, Novo Nordisk and Lundbeck, where he led R&D in oncology, autoimmunity and neurology. He spent five years in business development at Lundbeck, leading in-licensing and M&A. He is Senior Scientific Director at the Lundbeck Foundation, managing its Frontiers Grants program, and has authored more than 100 papers, book chapters, reviews and patents.

Thomas Sager, PhD

Chief Executive officer Contera Pharma

Thomas has more than 24 years of experience in drug discovery and development in biotech and pharma. He spent over ten years in R&D leadership roles at H. Lundbeck A/S in neurology and psychiatry, and from 2012 to 2020 he was Vice President and Head of Business Development, Licensing and Scientific Assessment at Lundbeck, where he was involved in numerous licensing and M&A deals. Thomas holds a PhD in neuroscience, has authored more than 35 peer-reviewed papers, and has been CEO of Contera Pharma since 2020.

Jeehun Kim

Head of Research / Board member

Jeehun Kim is Executive Vice President and Head of the Research and Business Development Division at Bukwang Pharmaceutical, where he oversees business development, licensing, investments, regulatory affairs and R&D activities. He previously led the Business Development Division at GC Biopharma and held BD roles at Eisai, Roche and several Korean pharmaceutical companies. He has over 25 years of experience in the pharmaceutical industry, including approximately 10 years at global pharmaceutical companies. He is a licensed pharmacist, holds a Master’s degree in Pharmacy and an Executive MBA from Aalto University.